MHRA Approves Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in UK

According to a recent article, Revolo Biotherapeutics announced it has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for two Phase 2 clinical trials to analyze its…

Continue Reading MHRA Approves Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in UK
Rare Classroom: Uveitis
source: shutterstock

Rare Classroom: Uveitis

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

Continue Reading Rare Classroom: Uveitis
First Subject Dosed in Laquinimod Trial for Uveitis
Source: https://unsplash.com/photos/6F2mPewg2RA

First Subject Dosed in Laquinimod Trial for Uveitis

On December 10, 2021, biotechnology company Active Biotech shared that the first subject was dosed within a Phase 1 clinical trial evaluating laquinimod for non-infectious non-anterior uveitis. What is particularly…

Continue Reading First Subject Dosed in Laquinimod Trial for Uveitis
XIPERE Approved in US for Uveitis Complication
source: pixabay.com

XIPERE Approved in US for Uveitis Complication

According to a news release from biopharmaceutical company Clearside Biomedical, Inc. ("Clearside") and eye health business Bausch + Lomb, a revolutionary treatment called XIPERE (triamcinolone acetonide injectable suspension) was recently…

Continue Reading XIPERE Approved in US for Uveitis Complication
License Territory Expanded: ARVN001 for UME
source: pixabay.com

License Territory Expanded: ARVN001 for UME

When it comes to pharmaceuticals, licensed territory helps ensure that drugs within a certain territory are offered to patients. Exclusive licenses sometimes mean that pharmaceuticals are only available in specific…

Continue Reading License Territory Expanded: ARVN001 for UME
Health Canada Approves Hyrimoz for Ankylosing Spondylitis
stevepb / Pixabay

Health Canada Approves Hyrimoz for Ankylosing Spondylitis

According to GlobeNewswire, Health Canada has approved of a biosimilar, Hyrimoz, to treat ankylosing spondylitis and eight other rare conditions. Sandoz Canada is excited about this approval, as it expands…

Continue Reading Health Canada Approves Hyrimoz for Ankylosing Spondylitis